Salarius Pharmaceuticals ... (SLRX)
0.68
0.01 (1.24%)
At close: Apr 17, 2025, 3:52 PM
0.67
-1.44%
After-hours: Apr 17, 2025, 07:50 PM EDT
1.24% (1D)
| Bid | 0.61 |
| Market Cap | 1.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.58M |
| EPS (ttm) | -5.79 |
| PE Ratio (ttm) | -0.12 |
| Forward PE | -0.04 |
| Analyst | n/a |
| Ask | 0.72 |
| Volume | 47,221 |
| Avg. Volume (20D) | 278,712 |
| Open | 0.64 |
| Previous Close | 0.67 |
| Day's Range | 0.64 - 0.71 |
| 52-Week Range | 0.45 - 7.20 |
| Beta | 0.60 |
About SLRX
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategi...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 29, 2015
Employees 2
Stock Exchange NASDAQ
Ticker Symbol SLRX
Website https://www.salariuspharma.com
3 months ago
+133.76%
Salarius Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
